Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053677 · ClinicalTrials.gov registry record · Phase 3
Drug Treatment for Pathologic Gambling Disorder
A Phase 3 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 3
- Development phase
- 83
- Enrollment target
NCT00053677 is a Phase 3 study that has completed, run by University of Chicago. The registered enrollment target is 83 participants.
The verdict
NCT00053677, a Phase 3 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 83 participants
- Enrollment target
Study Summary
This study will establish the best dose of the drug naltrexone to treat patients with Pathological Gambling Disorder (PGD) and severe urge symptoms.
Interventions
- DRUG Placebo
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2002-12 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053677
The ClinicalTrials.gov registry entry for NCT00053677 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00053677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00053677 about?
NCT00053677 is a clinical study titled "Drug Treatment for Pathologic Gambling Disorder". This study will establish the best dose of the drug naltrexone to treat patients with Pathological Gambling Disorder (PGD) and severe urge symptoms.
What is the current status of trial NCT00053677?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 83 participants. The study started on 2002-12. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00053677?
The interventions under investigation include: Placebo (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT00053677?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.